Keros Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Keros Therapeutics has a total shareholder equity of $453.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $485.8M and $31.9M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$442.44m |
| Equity | US$453.95m |
| Total liabilities | US$31.87m |
| Total assets | US$485.82m |
Recent financial health updates
We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely
Sep 24
We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth
Jun 10Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Dec 25Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Sep 08Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Apr 29We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely
Jan 24Recent updates
Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?
Apr 23We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely
Sep 24We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth
Jun 10Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Dec 25Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Sep 08Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07
Aug 04Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Apr 29We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely
Jan 24Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Oct 10We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely
May 05Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?
Mar 13We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate
Jan 19Have Insiders Been Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Shares?
Nov 27Keros Therapeutics prices equity offering at $50
Nov 13Financial Position Analysis
Short Term Liabilities: KROS's short term assets ($463.1M) exceed its short term liabilities ($18.7M).
Long Term Liabilities: KROS's short term assets ($463.1M) exceed its long term liabilities ($13.2M).
Debt to Equity History and Analysis
Debt Level: KROS is debt free.
Reducing Debt: KROS has no debt compared to 5 years ago when its debt to equity ratio was 31.1%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KROS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: KROS has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 42.1% each year.